Rocket Pharmaceuticals, Inc. announced on March 27, 2026, that the FDA approved their gene therapy KRESLADI™ for treating severe leukocyte adhesion deficiency-I in pediatric patients. Additionally, they received a Rare Pediatric Disease Priority Review Voucher to enhance financial flexibility and shareholder value.